High Tide Reports Annualized Revenue Run-Rate of $600 Million and Enters German Medical Cannabis Market
I'm PortAI, I can summarize articles.
High Tide Inc. announced its expansion into the German medical cannabis market by acquiring a majority stake in Remexian Pharma GmbH. The company reported an annualized revenue run-rate of $600 million and an Adjusted EBITDA run-rate of over $42 million for 2025. High Tide surpassed 200 Canna Cabana store locations and 2 million Canadian Cabana Club members, with cumulative sales exceeding $2 billion since cannabis legalization in Canada.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments